Anteris Technologies Global Corp 8-K, filed Dec 1, 2025
Anteris Technologies Global Corp. (AVR)
8-K
2025-12-01
For: 2025-11-26
View Original
Added on
April 07, 2026
About this 8-K
Anteris Technologies Global Corp filed this 8-K on December 1, 2025, reporting on events of November 26, 2025.
Items reported
- Item 1.02: Ended a material agreement
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 26, 2025
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: +61 7
3152 3200
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.02. |
Termination of a Material Definitive Agreement.
|
On November 26, 2025, Anteris Technologies Global Corp. (the “Company”) notified 4C Medical Technologies, Inc. (“4C”) that it was not renewing the Second Amended and
Restated Supply and License Agreement, as amended (the “Supply Agreement”), between the Company and 4C, which provided for the supply by the Company to 4C of ADAPT® tissue used in 4C’s production of medical devices related to
transcatheter mitral valve and tricuspid valve regurgitation therapy and granted a limited license to the Company’s related sterilization methods in connection with use of ADAPT® tissue by 4C in its production of medical devices.
The Supply Agreement had a term expiring on June 1, 2026, at which time it would automatically renew for successive one-year terms unless either party provided written
notice of non-renewal 180 days prior thereto. The Company will not incur any early termination penalties in connection with its non-renewal of the Supply Agreement. The termination of this contract does not materially impact on the financial results
of the Company.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Anteris Technologies Global Corp.
|
||
|
Date: December 1, 2025
|
By:
|
/s/ Wayne Paterson
|
|
Name: Wayne Paterson
|
||
|
Title: Vice Chairman and Chief Executive Officer
|
||